Summary: Immunoassay of creatine kinase-MB provides numerical information, which makes it possible to estimate quantitatively the diagnostic performance following myocardial infarction. Two graphical methods for such an evaluation are presented. The relationship between technical sensitivity and specificity was analyzed using a continuous function, the receiver-operator characteristic curve. Using this function, a diagnostic threshold ("upper normal limit") was chosen, which balances both technical specificity and sensitivity on the first day following infarction. On the second and third days this threshold caused a progressive loss of technical sensitivity. The relationship between effectiveness and the prevalence of myocardial infarction in the tested population was evaluated with a nomogram correlating these two quantities. With the chosen diagnostic threshold, effectiveness is independent of prevalence on the first day, but the loss in technical sensitivity on subsequent days causes effectiveness to decay when the prevalence is high.
Introduction
Recently, a creatine kinase-MB assay has been developed _ f . , . , . ™ 1111\ j which relies on the immunological blocking of enzymatic Create kmaseicreatme kinase EC 2.7. nomogram relating test effectiveness to disease prevalence.
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Experimental Procedure
Subjects Patients with myocardial infarction (N=42) and patients with suspected but unconfirmed myocardial infarction (N=98) were investigated. These diagnostic classifications were established by a review of clinical history, laboratory data and electrocardiographic data following the patient's discharge. Samples were obtained on three days following infarction or following admission for suspected infarction (days 1, 2 and 3). Venous blood was collected in vacuum tubes (CORVAC R ; Corning Medical, 11 North Street, Medfield, MA 02052), analyzed immediately or stored for no more than 18 hours at 4°C until assayed.
Immunological assay of creatine kinase-MB A spectrophotometer equipped with a cuvette holder thermqstatted at 37°C was used (Model 25; Beckman Instruments Inc., Fullerton, CA 92634). The assay mixture consisted of 10 μΐ reagent containing: 100 mmol/1 triethanolamine buffer pH 7.0; 35 mmol/1 creatine phosphate; 20 mmol/1 glucose; 9 mmol/1 glutathione; 10 mmol/1 AMP; > 1.2 kU/1 glucose 6-phosphate dehydrogenase; 11.2 kU/1 hexokinase, and 800 U/l creatine kinase-MM inhibiting antibodies from the goat (E. Merck, Darmstadt, West-Germany). Diadenosine pentaphosphate was added to this assay mixture in a final concentration of 10 μπιοΐ/ΐ. Following addition of the sample, the mixture was preincubated for 7 minutes and the absorbance at 340 nm was then recorded for 3 minutes to calculate enzyme activity using a value of 6,3001 · mol" 1 · cm' 1 as the molar absorbance coefficient of NADPH. Results were expressed in U/l.
Electrophoretic assay of creatine kinase-MB
Creatine kinase isoenzymes were separated on 10g/l agarose gel and visualized by overlay with the creatine kinase assay mixture of Oliver (7) . Relative activities of isoenzyme fractions were estimated by densitometric scanning at 340 nm. Absolute activity of creatine kinase-MB was calculated by multiplying the relative activity of this fraction (percent) with the total creatine kinase activity.
Assays of total creatine kinase, aspartate aminotransferase (EC 2.6.1.1), lactate dehydrogenase (EC 1.1.1.27), and 2-hydroxybutyrate dehydrogenase All four enzymes were assayed at 37°C on a mechanized, kinetic enzyme analyzer (System TR; Beckman Instrument Inc.). The creatine kinase assay of Oliver (7), the aspartate aminotransferase assay ofAmador & Wacker (8), the lactate dehydrogenase assay of Gay.McComb &. Bowers (9) and the aspartate aminotransferase assay of Rosalki et al (10) were used.
Statistical analysis
The terms technical sensitivity, technical specificity and effectiveness were used as previously defined (11) . Technical sensitivity is the probability of a positive test among patients with an infarct, and technical specificity is the probability of a negative test among patients without an infarct: 
Results
To establish the relationships of the immunological creatine kinase-MB assay to other laboratory indicators of myocardial infarction, the activities measured by this assay were correlated with the creatine kinase-MB activities derived from electrophoretic separation, as well as with the total creatine kinase, aspartate arninotransferase, 2-hydroxybutyrate dehydrogenase and lactate dehydrogenase activities (tab. 1). Correlations with creatine kinase-MB by electrpphpresis, total creatine kinase and aspartate aminotransferase (three parameters known to be early indicators of myocardial infarction), were essentially equivalent, ranging from 0.62 to 0.68. Conversely, correlations both with 24iydroxybutyrate dehydrogenase and with lactate dehydrogenase, which are known to rise later following infarction, were lower. The interdependence of technical sensitivity and specificity of immunological creatine kinase-MB assays was analyzed by the ROC function ( fig. 1) . Findings from the first, second and third days (24 hour periods) following infarction were separated. Using different creatine kinase-MB values as decision thresholds to distinguish normal from elevated findings, results from infarcted patients were classified into true positives and false negatives to calculate technical sensitivity for each day. All results from uninfarcted patients were classified into true negatives and false positives to calculate technical specificity. Thus, as the decision threshold was raised stepwise from zero to 60 U/l in analyzing data from day one, technical sensitivity decreased while technical specificity increased, since a decreasing number of patients were classified as positives.
When an activity of 15 U/l was used to separate negatives from positives, the two technical properties were equivalently balanced with a sensitivity of 93% and a specificity of 95%. We have subsequently used this value as our criterion to distinguish normal from elevated creatine kinase-MB values. On the second and third days, the overall discriminatory power diminished increasingly as the ROC curves evidenced a less favorable relationship between sensitivity and specificity. Using again 15 U/l as the discriminatory threshold, sensitivity on the second day was 72%, and on the third day 28%. prevalence of patients with myocardial infarction in the tested population. With a discriminatory threshold of 15 U/l effectiveness was practically insensitive to disease prevalence on the first day. Using the same decision threshold on subsequent days produced a dramatic decay of effectiveness at high disease prevalence, whereas effectiveness at low prevalences was not similarly affected.
Discussion
Traditionally, the evaluation of new laboratory assays focuses on technical and biochemical properties. Much less attention is paid to the diagnostic performance of the assays, even though this is the most crucial determinant of practical utility. Opinions about the immunological creatinekinase-MB assay illustrate these views. From a purely biochemical viewpoint, the inability of this procedure to distinguish activity due to creatine kinase-BB from that due to creatine kinase-MB has caused concern. From a diagnostic viewpoint, a lack of chemical specificity in principle need not invalidate a procedure (12) . This is particularly true if interferences, such as creatine kinase-BB in blood, are rarely encountered (6).
Concern with technical aspects of creatine kinase-MB assay has led to modifications of reaction temperature (4, 5, 13, 14) , sulfhydryl activators (17, 18) , inhibitors of adenylate kinase (EC 2.7.4.3) (I.e. (16)) and blanking procedures. These variables are of secondary relevance for the present purpose. The important technical feature of immunological creatine kinase-MB assay is the quantitative nature of results which facilitates the statistical evaluation of diagnostic performance.
A useful assessment of diagnostic performance rests on two foundations: Scrupulous retrospective case review and analytical summation which facilitates cogent conclusions. Many previous evaluations of laboratory indicators of myocardial infarction fall short of dealing adequately with the following issues: The definition of the normal range used to classify the results, attention to the elapsed time since the pathogenic event, and inclusion of the prevalence of infarction in the tested population. Experimental observations can only become relevant to clinical practice if these points are properly considered.
First, a reference range derived previously from observations in subjects without myocardial infarction is generally used to separate physiological from pathological findings (14, 19, 20) . However, from a diagnostic viewpoint such a threshold usually is not the most appropriate. Joint consideration of findings typical for diseased subjects as well as nondiseased subjects is preferable (21) . The ROC function provides a convenient way to consider these groups simultaneously (22) . Technical sensitivity can be related to technical specificity in a continuous function. Thus, different decision thresholds can be selected to tailor optimal outcome in different circumstances. Further, the ROC function permits comparison of the same test applied in different conditions such as different stages in the evolution of myocardial infarction ( fig. 1) . Similarly, the overall discriminatory power of different tests can be contrasted with each other to select the best one.
Second, the diagnostic performance of enzyme assays is typically evaluated on the basis of serial measurements following myocardial infarction. If the calculated diagnostic properties, such as sensitivity and specificity do not relate the statistical odds to sampling at a specific time, biased conclusions result.
Frequently, the rules for the serial sampling or for the choice of selected values on which the calculation of technical sensitivity is based are not detailed (14, 19) . In other instances only peak enzyme activities in the series are utilized for analysis even though these occur at different times following infarction and can only be identified retrospectively (20) . However, the test's varying capabilities at different points in time is relevant, as patients present themselves for diagnosis at different intervals following infarction. For this reason, we have analyzed all observations from all patients after classifying them according to time since the infarct. The diagnostic power of creatine kinase and creatine kinase-MB is greatest within the first 24 hours after the onset of retrosternal pain (19, 23) . The later deterioration is due to a loss of technical sensitivity, while technical specificity remains unaffected ( fig. 1) . Third, any evaluation of diagnostic utility should include the prevalence of the diagnosed condition in the tested population. Two parameters of test performance which take prevalence into account have been proposed. These quantities have been called alternatively "positive and negative predictive value" (24) and "diagnostic sensitivity and specificity" (11) . The experience contained in these values can be condensed into a single number which has been termed the effectiveness of a test (11) . This quantity considers the odds of a true positive -and of a true negative jointly. Construction of a simple nomogram to survey effectiveness as a continuous function at different prevalences of disease requires only the values of technical sensitivity and specificity. Figure 2 shows that the diagnostic threshold chosen for creatine kinase-MB renders effectiveness independent of disease prevalence on the day of infarction when the assay has its greatest utility. On subsequent days that same threshold provides less technical sensitivity than a lower one might have, and consequently would compromise effectiveness most were there a high prevalence of infarcted patients in the tested population.
The inferences from these propositions are:
1. The relationship between technical sensitivity and specificity which should determine normal limits is conveniently visualized in the ROC curve. 2. The elapsed time since infarction should be explicitly considered when test performance is evaluated. 3. A nomogram of effectiveness provides a simple means to include and evaluate the influence of prevalences on test performance.
